Travere Therapeutics to present abstracts at ASN Kidney Week

Travere Therapeutics (TVTX) announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology, ASN, Kidney Week 2025 in Houston, TX, November 6-9. In focal segmental glomerulosclerosis, the Company will present: A late-breaking analysis from the DUPLEX Study demonstrating that patients treated with FILSPARI were more likely to reach proteinuria levels under 0.7 g/g when compared with the maximum labeled dose of irbesartan, and achievement of this threshold correlated with reduced risk of kidney failure irrespective of treatment arm. An analysis evaluating the relationship between the magnitude of proteinuria reduction at two years with FILSPARI compared to the maximum labeled dose of irbesartan and long-term kidney outcomes in a subset of DUPLEX aligned participants in the UK National Registry of Rare Kidney Diseases. Data showing that FILSPARI-treated children and FILSPARI-treated individuals with COL4A3-5 mutations achieved rapid and sustained reductions in proteinuria compared with the maximum labeled dose of irbesartan in the DUPLEX Study. Presentations in IgA nephropathy will include: New data from SPARTAN demonstrating that among RASI-naive patients, FILSPARI induced anti-inflammatory and anti-fibrotic effects. Real-world data reinforcing FILSPARI’s ability to consistently lower proteinuria and preserve kidney function. Two new analyses from PROTECT showing that, irrespective of time from diagnosis or severity of disease based on kidney biopsy.